Antineoplastic Combined Chemotherapy ProtocolsInflammationInflammation MediatorsChemotherapy, AdjuvantCytokinesAntineoplastic AgentsTumor Necrosis Factor-alphaInterleukin-8DoxorubicinNF-kappa BLipopolysaccharidesCisplatinMacrophagesInterleukin-6Mice, Inbred C57BLCells, CulturedCombined Modality TherapyToll-Like Receptor 4Signal TransductionToll-Like Receptor 2CyclophosphamideApoptosisCell Line, TumorDrug Resistance, NeoplasmTreatment OutcomeMice, KnockoutInterleukin-1betaMonocytesEtoposideCell LineRNA, MessengerBreast NeoplasmsSeoul virusPaclitaxelMyeloid Differentiation Factor 88Gene Expression RegulationChemokinesUp-RegulationInterleukin-1Time FactorsDose-Response Relationship, DrugImmunity, InnateNeoadjuvant TherapyToll-Like ReceptorsLung NeoplasmsNeoplasmsReverse Transcriptase Polymerase Chain ReactionDisease-Free SurvivalLungMethotrexateEpithelial CellsDisease Models, AnimalInterleukin-10Mice, Inbred BALB CAntineoplastic Agents, PhytogenicSurvival AnalysisNeoplasm StagingVinblastineAntimetabolites, AntineoplasticMicrogliaAntibiotics, AntineoplasticDrug Administration ScheduleAntineoplastic Agents, AlkylatingPrognosisEnzyme-Linked Immunosorbent AssayNeutrophilsBlotting, WesternSurvival RateChemokine CCL2CarboplatinMacrophage ActivationTaxoidsGene ExpressionDeoxycytidineFlow CytometryBleomycinAnti-Inflammatory AgentsEndothelial CellsInterferon-gammap38 Mitogen-Activated Protein KinasesDrug SynergismDown-RegulationCell ProliferationNitric Oxide Synthase Type IIHMGB1 ProteinToll-Like Receptor 9Organoplatinum CompoundsIntercellular Adhesion Molecule-1Toll-Like Receptor 6I-kappa B ProteinsCell SurvivalCyclooxygenase 2Macrophages, PeritonealMembrane GlycoproteinsNeoplasm Recurrence, LocalSepsisAntigens, CD14IfosfamideOvarian NeoplasmsTranscription Factor RelA